Tumor Biology

, Volume 37, Issue 7, pp 9951–9958 | Cite as

Elevated STMN1 promotes tumor growth and invasion in endometrial carcinoma

  • Xiaoying He
  • Yun Liao
  • Wen Lu
  • Gufeng Xu
  • Huan Tong
  • Jieqi Ke
  • Xiaoping Wan
Original Article


Overexpression of stathmin (STMN1) is closely linked to tumor metastases and poor prognosis in endometrial carcinoma (EC). However, the underlying mechanism is little known. In the present study, we investigated the expression of STMN1 in EC. Subsequently, we assessed the role of STMN1 in EC cell proliferation and migration. Our data show that STMN1 is upregulated in EC, and elevated expression of STMN1 is correlated positively with tumor stage and lymph node metastasis. In vitro, forced expression of STMN1 promoted cell invasion and migration. In contrast, knockdown of STMN1 inhibited cell aggressive behaviors. Moreover, the expression and the activity changes of matrix metalloproteinases (MMP)-2/9 were observed in EC cells after the cells being silenced or overexpression of STMN1. In conclusion, STMN1 is an oncogene and it enhances the growth and invasion of EC possibly by mediating the secretion and activation of MMP2 and MMP9 protein.


STMN1 Endometrial cancer MMP2 MMP9 Gelatin zymography 



Our study was supported by the National Natural Science Foundation of China (No. 81172476, No. 81272885, No. 81472427), the Science and Technology Commission of Shanghai Municipality (No. 13JC1404501), and the Doctoral Fund of Ministry of Education of China (No. 20120073110090).

Compliance with ethical standards

Conflicts of interest



  1. 1.
    Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015;65(1):5–29.CrossRefPubMedGoogle Scholar
  2. 2.
    Salvesen HB, Haldorsen IS, Trovik J. Markers for individualised therapy in endometrial carcinoma. Lancet Oncol. 2012;13(8):e353–61.CrossRefPubMedGoogle Scholar
  3. 3.
    Saso S, Chatterjee J, Georgiou E, Ditri AM, Smith JR, Ghaem-Maghami S. Endometrial cancer. BMJ. 2011;343:d3954.CrossRefPubMedGoogle Scholar
  4. 4.
    Galaal K, Al Moundhri M, Bryant A, Lopes AD, Lawrie TA. Adjuvant chemotherapy for advanced endometrial cancer. Cochrane Database Syst Rev. 2014;5:CD010681.Google Scholar
  5. 5.
    Balachandran R, Welsh MJ, Day BW. Altered levels and regulation of stathmin in paclitaxel-resistant ovarian cancer cells. Oncogene. 2003;22(55):8924–30.CrossRefPubMedGoogle Scholar
  6. 6.
    Wang X, Ren JH, Lin F, Wei JX, Long M, Yan L, et al. Stathmin is involved in arsenic trioxide-induced apoptosis in human cervical cancer cell lines via PI3K linked signal pathway. Cancer Biol Ther. 2010;10(6):632–43.CrossRefPubMedGoogle Scholar
  7. 7.
    Mistry SJ, Atweh GF. Therapeutic interactions between stathmin inhibition and chemotherapeutic agents in prostate cancer. Mol Cancer Ther. 2006;5(12):3248–57.CrossRefPubMedGoogle Scholar
  8. 8.
    Xu SG, Yan PJ, Shao ZM. Differential proteomic analysis of a highly metastatic variant of human breast cancer cells using two-dimensional differential gel electrophoresis. J Cancer Res Clin Oncol. 2010;136(10):1545–56.CrossRefPubMedGoogle Scholar
  9. 9.
    Kuang XY, Chen L, Zhang ZJ, Liu YR, Zheng YZ, Ling H, et al. Stathmin and phospho-stathmin protein signature is associated with survival outcomes of breast cancer patients. Oncotarget. 2015.Google Scholar
  10. 10.
    Liu X, Liu H, Liang J, Yin B, Xiao J, Li J, et al. Stathmin is a potential molecular marker and target for the treatment of gastric cancer. Int J Clin Exp Med. 2015;8(4):6502–9.PubMedPubMedCentralGoogle Scholar
  11. 11.
    Schimmack S, Taylor A, Lawrence B, Schmitz-Winnenthal H, Fischer L, Buchler MW, et al. Stathmin in pancreatic neuroendocrine neoplasms: a marker of proliferation and PI3K signaling. Tumour Biol: J Int Soc Oncodev Biol Med. 2015;36(1):399–408.CrossRefGoogle Scholar
  12. 12.
    Salvesen HB, Carter SL, Mannelqvist M, Dutt A, Getz G, Stefansson IM, et al. Integrated genomic profiling of endometrial carcinoma associates aggressive tumors with indicators of PI3 kinase activation. Proc Natl Acad Sci U S A. 2009;106(12):4834–9.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Trovik J, Wik E, Stefansson IM, Marcickiewicz J, Tingulstad S, Staff AC, et al. Stathmin overexpression identifies high-risk patients and lymph node metastasis in endometrial cancer. Clin Cancer Res: Off J Am Assoc Cancer Res. 2011;17(10):3368–77.CrossRefGoogle Scholar
  14. 14.
    Liao Y, Lu W, Che Q, Yang T, Qiu H, Zhang H, et al. SHARP1 suppresses angiogenesis of endometrial cancer by decreasing hypoxia-inducible factor-1alpha level. PLoS One. 2014;9(6):e99907.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Rubin CI, Atweh GF. The role of stathmin in the regulation of the cell cycle. J Cell Biochem. 2004;93(2):242–50.CrossRefPubMedGoogle Scholar
  16. 16.
    Rana S, Maples PB, Senzer N, Nemunaitis J. Stathmin 1: a novel therapeutic target for anticancer activity. Expert Rev Anticancer Ther. 2008;8(9):1461–70.CrossRefPubMedGoogle Scholar
  17. 17.
    Wik E, Birkeland E, Trovik J, Werner HM, Hoivik EA, Mjos S, et al. High phospho-stathmin (Serine38) expression identifies aggressive endometrial cancer and suggests an association with PI3K inhibition. Clin Cancer Res: Off J Am Assoc Cancer Res. 2013;19(9):2331–41.CrossRefGoogle Scholar
  18. 18.
    Grybos A, Bar J. The relationships between the immunoexpression of KAI1, MMP-2, MMP-9 and steroid receptors expression in endometrial cancer. Folia Histochemica Et Cytobiologica / Pol Acad Sci, Pol Histochem Cytochem Soc. 2014;52(3):187–94.CrossRefGoogle Scholar
  19. 19.
    Di Nezza LA, Misajon A, Zhang J, Jobling T, Quinn MA, Ostor AG, et al. Presence of active gelatinases in endometrial carcinoma and correlation of matrix metalloproteinase expression with increasing tumor grade and invasion. Cancer. 2002;94(5):1466–75.CrossRefPubMedGoogle Scholar
  20. 20.
    Iurlaro M, Loverro G, Vacca A, Cormio G, Ribatti D, Minischetti M, et al. Angiogenesis extent and expression of matrix metalloproteinase-2 and -9 correlate with upgrading and myometrial invasion in endometrial carcinoma. Eur J Clin Invest. 1999;29(9):793–801.CrossRefPubMedGoogle Scholar
  21. 21.
    Fu X, Feng J, Zeng D, Ding Y, Yu C, Yang B. PAK4 confers cisplatin resistance in gastric cancer cells via PI3K/Akt- and MEK/Erk-dependent pathways. Biosci Rep. 2014.Google Scholar
  22. 22.
    Wells CM, Abo A, Ridley AJ. PAK4 is activated via PI3K in HGF-stimulated epithelial cells. J Cell Sci. 2002;115(Pt 20):3947–56.CrossRefPubMedGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2016

Authors and Affiliations

  • Xiaoying He
    • 1
  • Yun Liao
    • 2
  • Wen Lu
    • 3
  • Gufeng Xu
    • 2
  • Huan Tong
    • 4
  • Jieqi Ke
    • 4
  • Xiaoping Wan
    • 3
  1. 1.Department of Obstetrics and GynecologyShanghai Jiao Tong University Affiliated International Peace Maternity and Child Health HospitalShanghaiChina
  2. 2.Department of Obstetrics and Gynecology, Women’s Hospital, School of MedicineZhejiang UniversityHangzhouChina
  3. 3.Department of GynecologyTongji University School of Medicine Affiliated Shanghai First Maternity and Infant HospitalShanghaiChina
  4. 4.Department of Obstetrics and GynecologyShanghai Jiao Tong University Affiliated First People’s HospitalShanghaiChina

Personalised recommendations